Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The programmed cell death-1 (PD-1) pathway is a novel therapeutic target in immune checkpoint therapy for cancer. Nivolumab, an anti-PD-1 monoclonal antibody, blocks PD-1 and can restore anti-cancer immune responses by disrupting the signal that inhibits T-cell activation. Nivolumab may induce endocrine-related adverse events, including hypophysitis, autoimmune thyroiditis, and type 1 diabetes mellitus. Here we report a 68-year-old female patient with advanced renal cell carcinoma who was treated with nivolumab. She had positive anti-thyroglobulin antibodies and anti-thyroid peroxidase antibodies with slightly elevated thyroid-stimulating hormone (9.048 μU/mL), and was diagnosed as chronic thyroiditis with subclinical hypothyroidism before nivolumab therapy. She developed painless thyroiditis after the first cycle of the therapy (Day 14). At the 7th cycle of nivolumab therapy (Day 98), hyperglycemia (473 mg/dL) was noted, whereas glycated hemoglobin level was 6.9%. Islet-related autoantibodies were all negative. The glucagon tolerance test showed complete depletion of insulin. Human leukocyte antigen typing showed haplotype DRB1*09:01-DQB1*03:03, which was reported to be closely associated with type 1 diabetes mellitus in Japan. Fulminant type 1 diabetes mellitus was diagnosed, and she was immediately treated with multiple daily injections of insulin. Fulminant type 1 diabetes mellitus is characterized by rapid-onset diabetic ketoacidosis, and negative islet-related autoantibodies, and was proposed as a novel subtype of non-autoimmune diabetes. Preceding painless thyroiditis with positive thyroid autoantibodies observed in the present case, however, raises the possibility that autoimmune mechanisms are involved in the pathogenesis of nivolumab-induced fulminant type 1 diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s062 · Cited by 1,817
Chronic Autoimmune Thyroiditis
Dayan, C. M., & Daniels, G. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350206 · Cited by 904
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., & Torino, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4075 · Cited by 403
Chae, Y. K., Chiec, L., Mohindra, N., Gentzler, R., Patel, J., & Giles, F. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-016-1913-7 · Cited by 121
Cited by
Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002435 · Cited by 917
Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review
de Filette, J. M. K., Pen, J. J., Decoster, L., Vissers, T., Bravenboer, B., Van der Auwera, B. J., Gorus, F. K., Roep, B. O., Aspeslagh, S., Neyns, B., et al. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0291 · Cited by 275
Bajwa, R., Cheema, A., Khan, T., Amirpour, A., Paul, A., Chaughtai, S., Patel, S., Patel, T., Bramson, J., Gupta, V., et al. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3750 · Cited by 179
“The 54 case reports were reviewed in detail with results shown in Table 2 [53-94].”
Tan, M. H., Iyengar, R., Mizokami-Stout, K., Yentz, S., MacEachern, M. P., Shen, L. Y., Redman, B., & Gianchandani, R. (2019) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-018-0073-4 · Cited by 172
Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: A systematic review
Zhao, Z., Wang, X., Bao, X.-Q., Ning, J., Shang, M., & Zhang, D. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02699-1 · Cited by 30
Metadata
- Authors
- Sakurai, K., Niitsuma, S., Sato, R., Takahashi, K., & Arihara, Z.
- Venue
- The Tohoku Journal of Experimental Medicine
- Publisher
- Tohoku University Medical Press
- Published
- 2018
- Volume
- 244
- Issue
- 1
- Pages
- 33-40
- ISSN
- 0040-8727 (ISSN-L)
- 1349-3329
- OpenAlex
- W2793083748
- Cited by
- 52
- References
- 5
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab. https://app.cochat.ai/papers/10.1620/tjem.244.33
- The paper
- Sakurai, K., Niitsuma, S., Sato, R., Takahashi, K., & Arihara, Z. (2018). Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab. The Tohoku Journal of Experimental Medicine. https://doi.org/10.1620/tjem.244.33
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.